Börsipäev 24. juuni
Log in or create an account to leave a comment
-
Täna kauplevad enamus Euroopa indekseid miinuspoolel (DAX -1,1%) ja seda peamiselt seetõttu, et Kreeka võlausaldajad on tagasi lükanud Kreeka viimati esitatud ettepaneku.
Ka USA futuurid on päeva alustamas punases, kaubeldes ca 0,20% miinuspoolel.
Tõenäoliselt kulgeb ülejäänud päev Kreeka uudiste tuules, sest muidu olulisi majandusnäitajaid enne homsest USA-st tulemas pole. -
Gapping up
In reaction to strong earnings/guidance: MEET +23.6%, LEN +4.1%
M&A news: MCGC +0.9% (received a revised acquisition proposal from HC2 Holdings (HCHC)), MR +0.8% (forms special committee to evaluate previously announced $30/share 'Going Private' proposal)
Other news: CPXX +13.4% (announces positive induction response results from Phase 3 Study of CPX-351 in patients with high-risk (secondary) acute Myeloid Leukemia), ARTX +13.2% (announces $8.7 mln in New Orders), NVGN +8.3% (cytotoxic chemotherapy drug, Anisina, has been fast-tracked by the Company to be ready to come into clinics), BOX +6% (Box and IBM (IBM) announce partnership to collaborate in cloud-based services ), NKTR +5% (to replace CASY in the S&P SmallCap 600), SMI +4.7% (SMI, Huawei, and QCOM form JV), CREG +4.5% (enters into a repurchase agreement for the waste heat power generation, with Sinosteel Group Jilin Ferroalloys), KITE +4.4% (CEO discusses co's immunotherapy treatment on CNBC), MELA +3.8% (modestly ticking higher after yesterday's weakness), TKAI +3.3% (initiates a Phase 3 clinical trial of Galeterone, in men with metastatic castration-resistant prostate cancer), NFLX +2.9% (announces seven-for-one stock split), ORAN +2.6% (announced the expansion and availability in Asia Pacific), WATT +2.3% (following yesterday's ~25% move higher), CNIT +1.8% (reports a strategic agreement with the Linyi municipal government, to implement its the 'CNIT Internet + Smart Linyi' project), CASY +1% (to replace AOL int he S&P MidCap 400), VNDA +0.8% (reports positive results from the long-term maintenance REPRIEVE), PSTI +0.8% (granted Australian patent for 3D Cell Expansion Technology & use of PLX cells in broad range of indications)
Analyst comments: CPRX +8.5% (initiated with a Buy at MLV & Co; $14 tgt; also - reports top-line results in a proof-of-concept trial of Vigabatrin), EA +2.1% (upgraded to Buy from Hold at Jefferies), VMW +1.8% (added to Conviction Buy List at Goldman), AMAT +1.7% (added to Conviction Buy List at Goldman), F +1.6% (upgraded to Buy from Neutral at Goldman), RDS.A +1.4% (upgraded to Buy from Hold at Deutsche Bank), CCL +1.1% (target raised to $60 at Stifel), BHP +0.8% (upgraded to Neutral from Underperform at Credit Suisse), AVGO +0.8% (initiated with a Buy at Argus; tgt $163), RCL +0.7% (upgraded to Buy from Neutral at Goldman), CORR +0.7% (upgraded to Outperform at RBC Capital Mkts), TERP +0.7% (added to Analyst Focus List at JP Morgan)
Gapping down
In reaction to disappointing earnings/guidance: KOOL -13.1%, EXFO -7.3%, WSCI -0.9%, PRXL -0.8%
M&A news: DEG -4.5% (Delhaize Group and Ahold (AHONY) announce intention to combine through a merger of equals), SPLS -3.7% (NYPost discusses that a SPLS and Office Depot (ODP) merger might be less likely following judge's decision to block Sysco (SYY) / US Foods merger)
Other news: LOCM -61.1% (discloses filing of a voluntary petition in the United States Bankruptcy Court for the Central District of California for reorganization relief under Chapter 11 of title 11 of the United States Code), TTHI -50.5% (reports that its Phase 2/3 clinical study of ELND005 did not meet its primary endpoint), ADHD -16.1% (reports results from a Phase 2 clinical trial of MDX for Fragile X syndrome; study did not meet primary endpoint), NBG -7.1% (reports Greece's creditors rejected latest proposal), FEYE -3.2% (still checking; may be in symp with FTNT dg's (see below)), MOFG -2.3% (announced private placement for gross proceeds of ~$8.4 mln; agreed to sell an aggregate of 300,000 newly issued shares of common stock at a purchase price of $28.00 per share to existing shareholders), ARO -2.2% (to be replaced in the S&P SmallCap 600 by TopBuild), PQ -1.9% (to be replaced in the S&P 600 by Unit Corp), NYLD -1.7% (prices offering of 24,520,000 shares of its Class C common stock at a price of $22.00 per share), SYY -1.6% (confirmed that a Federal Court ruled to block co's merger with US Foods), PGN -1.6% (to be replaced in the S&P SmallCap 600 by Semtech), ASTI -1.5% (received non-compliance notice from Nasdaq), SNR -1.5% (prices offering of 17,500,000 shares of its common stock at a public offering price of $13.75 per share), AMBA -1.5% (pulling back following yday's strength), BLUE -1.3% (prices offering of 2,941,176 shares of common stock at $170.00 per share), CNHI -1.2% (prices $600 mln of 3.875% notes due 2018), ATI -1% (to be replaced in the S&P 500 by Columbia Pipeline Group; to replace Unit Corp in the S&P MidCap 400)
Analyst comments: FTNT -3.3% (downgraded to Neutral from Buy at Citigroup; downgraded to Neutral at Robert W. Baird), IPHI -2.5% (downgraded to Market Perform from Outperform), ESPR -1.8% (assumed/downgraded to Neutral from Outperform at Credit Suisse), GM -1.4% (downgraded to Neutral from Buy at Goldman), C -0.8% (downgraded to Hold from Buy at Deutsche Bank), ALV -0.7% (downgraded to Sell from Neutral at Goldman), GS -0.6% (downgraded to Hold from Buy at Deutsche Bank)
Allikas: Briefing.com
